Across TCGA pan-cancer cohorts, ZNF663P Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNF663P data layer compared with 22 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher ZNF663P Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF663P expression acts as an unfavorable survival marker.

SARC, SKCM, and BRCA are the cancer types where ZNF663P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.098	0.611	.006	6	view →
SKCM	DFS	Median	All	0.192	0.757	.022	6	view →
BRCA	OS	Median	All	0.181	0.579	.029	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ZNF663P tumor-vs-normal RNA expression · all ZNF663P data types